Keyphrases
Older Adults
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Immune Checkpoint Inhibitors
100%
Survival Outcomes
100%
Real-world Use
100%
Autoimmune Disease
42%
Poor Performance Status
42%
Comorbid Conditions
28%
Multivariable
14%
Overall Survival
14%
Median Overall Survival
14%
Poor Prognosis
14%
Patient Characteristics
14%
Surveillance Epidemiology
14%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
14%
1-year Survival
14%
Initial Diagnosis
14%
Radiotherapy
14%
Systemic Therapy
14%
I to
14%
Stage IV Disease
14%
Squamous Histology
14%
Multiple Comorbidities
14%
Treatment Initiation
14%
Nivolumab
14%
Oncology Practice
14%
Pembrolizumab
14%
Linked Database
14%
Stage IV Non-small Cell Lung Cancer
14%
Platinum Doublets
14%
Medicine and Dentistry
Lung Cancer
100%
Immune Checkpoint Inhibitor
100%
Overall Survival
28%
Survival Rate
14%
Disease
14%
Radiation Therapy
14%
Cohort Effect
14%
Patient Characteristics
14%
Autoimmune Disease
14%
Oncology
14%
Systemic Therapy
14%
Nivolumab
14%
Pembrolizumab
14%
Comorbidity
14%